BR112020002012A8 - Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39 - Google Patents

Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39

Info

Publication number
BR112020002012A8
BR112020002012A8 BR112020002012A BR112020002012A BR112020002012A8 BR 112020002012 A8 BR112020002012 A8 BR 112020002012A8 BR 112020002012 A BR112020002012 A BR 112020002012A BR 112020002012 A BR112020002012 A BR 112020002012A BR 112020002012 A8 BR112020002012 A8 BR 112020002012A8
Authority
BR
Brazil
Prior art keywords
antibodies
methods
compositions
homologues
isoforms
Prior art date
Application number
BR112020002012A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112020002012A2 (pt
Inventor
Soros Vanessa
Kovalenko Maria
Corbin John
Beers Courtney
Fredrick Widboom Paul
Robert Warfield Joseph
Original Assignee
Tizona Therapeutics
Trishula Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tizona Therapeutics, Trishula Therapeutics Inc filed Critical Tizona Therapeutics
Publication of BR112020002012A2 publication Critical patent/BR112020002012A2/pt
Publication of BR112020002012A8 publication Critical patent/BR112020002012A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
BR112020002012A 2017-07-31 2018-07-30 Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39 BR112020002012A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539527P 2017-07-31 2017-07-31
US62/539,527 2017-07-31
PCT/US2018/044449 WO2019027935A1 (en) 2017-07-31 2018-07-30 ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES

Publications (2)

Publication Number Publication Date
BR112020002012A2 BR112020002012A2 (pt) 2020-09-01
BR112020002012A8 true BR112020002012A8 (pt) 2022-06-28

Family

ID=65233024

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020002012A BR112020002012A8 (pt) 2017-07-31 2018-07-30 Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39

Country Status (22)

Country Link
US (6) US20190062448A1 (enExample)
EP (1) EP3661966A4 (enExample)
JP (4) JP7113071B2 (enExample)
KR (2) KR20240153413A (enExample)
CN (2) CN111448211B (enExample)
AR (1) AR112639A1 (enExample)
AU (1) AU2018312251B2 (enExample)
BR (1) BR112020002012A8 (enExample)
CA (1) CA3071540A1 (enExample)
CL (1) CL2020000281A1 (enExample)
CO (1) CO2020001983A2 (enExample)
CR (1) CR20200101A (enExample)
DO (1) DOP2020000021A (enExample)
IL (2) IL316357A (enExample)
MX (1) MX2020001270A (enExample)
MY (1) MY202018A (enExample)
PE (1) PE20200617A1 (enExample)
PH (1) PH12020500240A1 (enExample)
SG (2) SG11202000820PA (enExample)
TW (2) TW202344516A (enExample)
WO (1) WO2019027935A1 (enExample)
ZA (1) ZA202000608B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2238170B1 (en) 2008-01-31 2016-11-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
CA3051640A1 (en) 2017-03-16 2018-09-20 Innate Pharma Compositions and methods for treating cancer
KR20240153413A (ko) 2017-07-31 2024-10-22 트리슐라 테라퓨틱스, 인코포레이티드 항-cd39 항체, 항-cd39 항체를 포함하는 조성물 및 항-cd39 항체를 사용하는 방법
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3765524A4 (en) * 2018-03-14 2021-12-22 Surface Oncology, Inc. ANTIBODIES THAT BIND TO CD39 AND THEIR USES
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
KR20210005894A (ko) 2018-05-03 2021-01-15 상하이 에피맙 바이오테라퓨틱스 컴퍼니, 리미티드 Pd-1 및 lag-3에 대한 높은 친화성 항체 및 이로부터 제조된 이중특이성 결합 단백질
BR112020024412A8 (pt) 2018-06-18 2023-03-21 Innate Pharma Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
BR112021016537A2 (pt) * 2019-02-21 2021-10-26 Trishula Therapeutics, Inc. Terapia de combinação envolvendo anticorpos anti-cd39 e anticorpos anti-pd-1 ou anti-pd-l1
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
TWI883032B (zh) * 2019-08-12 2025-05-11 中國大陸商北京恩瑞尼生物科技股份有限公司 藉由adcc靶向cd39表現細胞促進及增強t細胞介導免疫反應之方法及組合物
CN112714768B (zh) 2019-08-27 2025-02-18 科望(苏州)生物医药科技有限公司 新型抗cd39抗体
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
CN110407941B (zh) * 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
US12391756B2 (en) 2019-11-05 2025-08-19 Jacobio Pharmaceuticals Co., Ltd. Binding molecule specific for CD39 and use thereof
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
AU2021245936A1 (en) * 2020-04-03 2022-11-03 Trishula Therapeutics, Inc. Combination therapy involving anti-CD39 antibodies and adoptive cell therapy
WO2021262597A2 (en) 2020-06-22 2021-12-30 Ngm Biopharmaceuticals, Inc. Lair-1-binding agents and methods of use thereof
WO2021260966A1 (ja) * 2020-06-25 2021-12-30 学校法人埼玉医科大学 アデノシン産生酵素を標的とする組成物
EP4232071A4 (en) * 2020-10-23 2024-08-28 Asher Biotherapeutics, Inc. FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
AU2021389989A1 (en) * 2020-11-27 2023-06-08 Elpiscience (Suzhou) Biopharma, Ltd. Novel conjugate molecules targeting cd39 and tgfβeta
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
CA3219181A1 (en) 2021-05-19 2022-11-24 Yik Andy Yeung Il-21 polypeptides and targeted constructs
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
CN118715243A (zh) * 2022-01-24 2024-09-27 上海华奥泰生物药业股份有限公司 Cd39抗原结合蛋白及其应用
WO2023164872A1 (en) * 2022-03-03 2023-09-07 Arcus Biosciences, Inc. Anti-cd39 antibodies and use thereof
AR128688A1 (es) 2022-03-03 2024-06-05 Arcus Biosciences Inc Anticuerpos anti-cd39 y uso de los mismos
AU2023227505A1 (en) * 2022-03-04 2024-09-12 AbbVie Deutschland GmbH & Co. KG Combinations with an anti human cd39 antibody, an anti human pd-1 antibody, and chemotherapy in gastric cancer
US20250215105A1 (en) 2022-03-25 2025-07-03 Brightpath Biotherapeutics Co., Ltd. Anti-cd39 antibody
CA3256033A1 (en) 2022-04-13 2023-10-19 Arcus Biosciences, Inc. POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH-2
WO2024030956A2 (en) * 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
WO2024115935A1 (en) 2022-11-29 2024-06-06 Inserm Methods for the treatment of b-cell lymphoma using cd39 inhibitors
EP4669350A1 (en) * 2023-02-24 2025-12-31 Institut National de la Santé et de la Recherche Médicale ENDOMETRIOSIS TREATMENT METHODS
CN119462930A (zh) * 2023-05-24 2025-02-18 深圳市先康达生命科学有限公司 靶向人Nectin4蛋白的抗体或其片段和应用
KR102879536B1 (ko) * 2023-06-09 2025-10-31 주식회사 브이티 시카 추출물이 함침된 마이크로 니들을 유효성분으로 포함하는 화장료 조성물 및 이의 제조방법
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN117986364B (zh) * 2023-12-27 2025-01-21 华润生物医药有限公司 特异性结合cd39的纳米抗体及其用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69605181T3 (de) 1995-01-18 2006-08-24 Roche Diagnostics Gmbh Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern
WO1996032471A2 (en) 1995-04-10 1996-10-17 Universite De Sherbrooke Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology
US6476211B1 (en) 1998-07-16 2002-11-05 Hyseq, Inc. Methods and materials relating to CD39-like polypeptides
US6447771B1 (en) 1999-03-19 2002-09-10 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
US6387645B1 (en) 1998-07-16 2002-05-14 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
WO2000004041A2 (en) 1998-07-16 2000-01-27 Hyseq, Inc. Methods and molecules relating to cd39-like polypeptides
US6350447B1 (en) 1999-01-29 2002-02-26 Hyseq, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6780977B1 (en) 1999-01-29 2004-08-24 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6899875B1 (en) 1999-01-29 2005-05-31 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6335013B1 (en) 1999-03-19 2002-01-01 Hyseq, Inc. Methods and materials relating to CD39-like polypeptides
WO2003052121A2 (en) 2001-12-17 2003-06-26 Beth Israel Deaconess Medical Center Method of reducing angiogenesis
US20050037382A1 (en) 2003-04-08 2005-02-17 Robson Simon C. Methods and compositions for treating and preventing autoimmune disorders
WO2006111986A1 (en) 2005-04-19 2006-10-26 Fondazione Santa Lucia I.R.C.C.S. Method for the detection and the isolation of immunosuppressive regulatory t cells and uses thereof
WO2009021754A2 (en) * 2007-08-15 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Monospecific and multispecific antibodies and method of use
EP2211908A2 (en) 2007-11-30 2010-08-04 Bristol-Myers Squibb Company Conjugates of anti-rg-1 antibodies
EP2238170B1 (en) 2008-01-31 2016-11-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
WO2012085132A1 (en) * 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
US10633451B2 (en) * 2012-02-03 2020-04-28 Hoffmann-La Roche Inc. Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
MX2020000621A (es) * 2014-04-01 2020-11-12 Rubius Therapeutics Inc Composiciones para usarse en inmunomodulacion.
WO2016073845A1 (en) 2014-11-07 2016-05-12 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
US10100129B2 (en) 2014-11-21 2018-10-16 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
US20180140724A1 (en) 2015-05-27 2018-05-24 The Trustees Of Columbia University In The City Of New York Tumor Deliverable Iron and Protein Synthesis Inhibitors as a New Class of Drugs for the Diagnosis and Treatment of Cancer
WO2017059095A1 (en) 2015-10-01 2017-04-06 Potenza Therapeutics, Inc. Anti-tigit antigen-binding proteins and methods of use thereof
WO2017064043A1 (en) 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
US20190153113A1 (en) 2015-11-23 2019-05-23 Innate Pharma Cd39 vascular isoform targeting agents
WO2017157948A1 (en) 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
EP3744348B1 (en) 2016-05-06 2022-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml)
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
CA3047988A1 (en) 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
CA3051640A1 (en) 2017-03-16 2018-09-20 Innate Pharma Compositions and methods for treating cancer
KR20240153413A (ko) 2017-07-31 2024-10-22 트리슐라 테라퓨틱스, 인코포레이티드 항-cd39 항체, 항-cd39 항체를 포함하는 조성물 및 항-cd39 항체를 사용하는 방법
JP7274469B2 (ja) 2017-10-06 2023-05-16 イナート・ファルマ・ソシエテ・アノニム Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復
WO2019096900A1 (en) 2017-11-15 2019-05-23 Innate Pharma Potentiating the effect of atp release
EP3765524A4 (en) 2018-03-14 2021-12-22 Surface Oncology, Inc. ANTIBODIES THAT BIND TO CD39 AND THEIR USES
TWI883032B (zh) 2019-08-12 2025-05-11 中國大陸商北京恩瑞尼生物科技股份有限公司 藉由adcc靶向cd39表現細胞促進及增強t細胞介導免疫反應之方法及組合物
CN112714768B (zh) 2019-08-27 2025-02-18 科望(苏州)生物医药科技有限公司 新型抗cd39抗体
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
CN110407941B (zh) 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途

Also Published As

Publication number Publication date
BR112020002012A2 (pt) 2020-09-01
US20250026850A1 (en) 2025-01-23
PE20200617A1 (es) 2020-03-11
TW202344516A (zh) 2023-11-16
CR20200101A (es) 2020-04-15
EP3661966A4 (en) 2021-07-21
JP2020530289A (ja) 2020-10-22
CN118978594A (zh) 2024-11-19
EP3661966A1 (en) 2020-06-10
IL316357A (en) 2024-12-01
DOP2020000021A (es) 2020-08-16
ZA202000608B (en) 2022-07-27
US11345757B2 (en) 2022-05-31
AU2018312251B2 (en) 2025-02-20
JP2022145720A (ja) 2022-10-04
CN111448211A (zh) 2020-07-24
CO2020001983A2 (es) 2020-04-01
KR20240153413A (ko) 2024-10-22
MY202018A (en) 2024-03-29
PH12020500240A1 (en) 2021-01-04
TW201920277A (zh) 2019-06-01
IL272367B1 (en) 2025-04-01
WO2019027935A1 (en) 2019-02-07
CL2020000281A1 (es) 2020-12-18
SG10202111869SA (en) 2021-11-29
KR20200033928A (ko) 2020-03-30
TWI798242B (zh) 2023-04-11
IL272367A (en) 2020-03-31
MX2020001270A (es) 2020-09-22
US20220340680A1 (en) 2022-10-27
US20190062448A1 (en) 2019-02-28
KR102718932B1 (ko) 2024-10-17
IL272367B2 (en) 2025-08-01
US20210403593A1 (en) 2021-12-30
AU2018312251A1 (en) 2020-02-20
JP7113071B2 (ja) 2022-08-04
CA3071540A1 (en) 2019-02-07
SG11202000820PA (en) 2020-02-27
US20210009708A1 (en) 2021-01-14
CN111448211B (zh) 2024-06-07
JP7690085B2 (ja) 2025-06-09
JP2025116106A (ja) 2025-08-07
AR112639A1 (es) 2019-11-20
RU2020108524A (ru) 2021-09-02
JP2024079809A (ja) 2024-06-11
US20220372163A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
BR112020002012A8 (pt) Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
BR112018070260A2 (pt) receptores quiméricos e métodos de uso dos mesmos
BR112021012667A2 (pt) Proteínas de ligação anti-pd-1 e métodos de uso destas
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
BR112017023868A2 (pt) anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos
BR112018013407A2 (pt) anticorpos e conjugados dos mesmos
BR112018006237A2 (pt) proteínas de ligação a pd-1 e métodos de uso das mesmas
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
BR112017000671A2 (pt) moléculas com especificidade para cd79 e cd22
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112019005139A2 (pt) anticorpos anti-il-33 e usos dos mesmos
BR112018075222A2 (pt) anticorpos anti-tnfrsf25
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
BR112019005783A2 (pt) agentes de ligação monoclonal com cmet, conjugados de fármaco dos mesmos e usos dos mesmos

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: TRISHULA THERAPEUTICS, INC. (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]